FR2984363B1 - Procede pour le diagnostic ou le pronostic in vitro du cancer du sein - Google Patents

Procede pour le diagnostic ou le pronostic in vitro du cancer du sein

Info

Publication number
FR2984363B1
FR2984363B1 FR1162095A FR1162095A FR2984363B1 FR 2984363 B1 FR2984363 B1 FR 2984363B1 FR 1162095 A FR1162095 A FR 1162095A FR 1162095 A FR1162095 A FR 1162095A FR 2984363 B1 FR2984363 B1 FR 2984363B1
Authority
FR
France
Prior art keywords
prognosis
breast cancer
vitro diagnosis
vitro
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1162095A
Other languages
English (en)
Other versions
FR2984363A1 (fr
Inventor
Philippe Perot
Francois Mallet
Nathalie Mugnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Priority to FR1162095A priority Critical patent/FR2984363B1/fr
Priority to PCT/FR2012/052957 priority patent/WO2013093316A2/fr
Priority to CN201280063479.2A priority patent/CN104024435A/zh
Priority to EP12810393.4A priority patent/EP2794914A2/fr
Priority to US14/367,634 priority patent/US20150018222A1/en
Publication of FR2984363A1 publication Critical patent/FR2984363A1/fr
Application granted granted Critical
Publication of FR2984363B1 publication Critical patent/FR2984363B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR1162095A 2011-12-20 2011-12-20 Procede pour le diagnostic ou le pronostic in vitro du cancer du sein Expired - Fee Related FR2984363B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1162095A FR2984363B1 (fr) 2011-12-20 2011-12-20 Procede pour le diagnostic ou le pronostic in vitro du cancer du sein
PCT/FR2012/052957 WO2013093316A2 (fr) 2011-12-20 2012-12-17 Procede pour le diagnostic ou le pronostic, in vitro, du cancer du sein
CN201280063479.2A CN104024435A (zh) 2011-12-20 2012-12-17 用于乳腺癌的体外诊断或预后的方法
EP12810393.4A EP2794914A2 (fr) 2011-12-20 2012-12-17 Procede pour le diagnostic ou le pronostic, in vitro, du cancer du sein
US14/367,634 US20150018222A1 (en) 2011-12-20 2012-12-17 Method for in vitro diagnosis or prognosis of breast cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1162095A FR2984363B1 (fr) 2011-12-20 2011-12-20 Procede pour le diagnostic ou le pronostic in vitro du cancer du sein

Publications (2)

Publication Number Publication Date
FR2984363A1 FR2984363A1 (fr) 2013-06-21
FR2984363B1 true FR2984363B1 (fr) 2017-11-24

Family

ID=47505255

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1162095A Expired - Fee Related FR2984363B1 (fr) 2011-12-20 2011-12-20 Procede pour le diagnostic ou le pronostic in vitro du cancer du sein

Country Status (5)

Country Link
US (1) US20150018222A1 (fr)
EP (1) EP2794914A2 (fr)
CN (1) CN104024435A (fr)
FR (1) FR2984363B1 (fr)
WO (1) WO2013093316A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100185A (zh) * 2018-10-26 2020-05-05 上海锐赛生物技术有限公司 Ct-rcc herv-e来源的ctl表位肽、肽库及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
EP2339035A1 (fr) * 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Rétrovirus endogène régulé en hausse dans le cancer de la prostate
EP1521594B1 (fr) * 2001-12-07 2013-10-02 Novartis Vaccines and Diagnostics, Inc. Polypeptides de retrovirus endogenes lies a la transformation oncogenique
US7534875B2 (en) * 2003-11-03 2009-05-19 Exagen Diagnostics, Inc. Compositions for glioma classification
US20090215711A1 (en) * 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
FR2984364A1 (fr) * 2011-12-20 2013-06-21 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer de l'ovaire
FR2984362B1 (fr) * 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du poumon
FR2984361B1 (fr) * 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du testicule

Also Published As

Publication number Publication date
FR2984363A1 (fr) 2013-06-21
CN104024435A (zh) 2014-09-03
EP2794914A2 (fr) 2014-10-29
WO2013093316A2 (fr) 2013-06-27
WO2013093316A3 (fr) 2013-10-24
US20150018222A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1200933A1 (zh) 改善炎性腸病診斷的方法
HK1203091A1 (en) Methods for diagnosis of lung cancer
HK1199754A1 (en) Method for monitoring, diagnosis and or prognosis of acute kidney injury in early stage
FR2944019B1 (fr) Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
HK1201329A1 (en) Method of predicting breast cancer prognosis
FR2977046B1 (fr) Diagnostic perfectionne pour aeronefs
EP2684157A4 (fr) Système et procédé pour une imagerie de seins à double énergie et/ou à injection d'un agent de contraste pour un dépistage, un diagnostic et une biopsie
GB2513275B (en) Biomarkers for Breast Cancer Prediction and Diagnosis
HK1187377A1 (zh) 用於對乳腺癌的轉移進行診斷、預後和治療的方法
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
EP2723866A4 (fr) Procédés de pronostic et/ou de diagnostic d'une maladie neurodégénérative, procédés d'identification de composés candidats et composés pour le traitement d'une maladie neurodégénérative
PT2737081T (pt) Método para prever a resposta a quimioterapia num doente que sofre de ou em risco de desenvolver cancro de mama recorrente
ZA201401326B (en) Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
HK1211345A1 (en) Methods of prognosis and diagnosis of cancer
EP2755559A4 (fr) Système à bras latéral pour biopsie mammaire
ZA201400500B (en) Use of the antibody i-3859 for the detection and diagnosis of cancer
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
HK1187962A1 (en) Method for the diagnosis of myeloid neoplasias and solid tumors and diagnostic kits
EP2880443A4 (fr) Méthodes et compositions pour le diagnostic et le pronostic du cancer du sein
FR2984361B1 (fr) Procede pour le diagnostic ou le pronostic in vitro du cancer du testicule
FR2984360B1 (fr) Procede pour le diagnostic ou le pronostic in vitro du cancer du colon
FR2984362B1 (fr) Procede pour le diagnostic ou le pronostic in vitro du cancer du poumon
FR2928659B1 (fr) Procede pour le diagnostic ou pronostic in vitro du cancer du testicule
SI3084442T1 (sl) Diagnostični reagenti za izboljšano in vivo ali in vitro celično posredovano diagnosticiranje tuberkuloze
EP2771695A4 (fr) Procédé de détection de cancers du sein

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20200905